James F. Oliviero III Sells 9,233 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Stock

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III sold 9,233 shares of the company’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $3.41, for a total transaction of $31,484.53. Following the completion of the sale, the chief executive officer now directly owns 3,785,350 shares of the company’s stock, valued at $12,908,043.50. This represents a 0.24 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Checkpoint Therapeutics Stock Down 3.1 %

CKPT stock traded down $0.10 during mid-day trading on Tuesday, hitting $3.13. 851,190 shares of the company were exchanged, compared to its average volume of 885,885. The firm has a market capitalization of $152.84 million, a P/E ratio of -1.70 and a beta of 1.36. The business has a fifty day simple moving average of $3.39 and a 200-day simple moving average of $2.99. Checkpoint Therapeutics, Inc. has a 12-month low of $1.38 and a 12-month high of $4.50.

Checkpoint Therapeutics (NASDAQ:CKPT) last announced its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.08). Research analysts predict that Checkpoint Therapeutics, Inc. will post -0.94 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. D. Boral Capital assumed coverage on shares of Checkpoint Therapeutics in a report on Monday, January 13th. They issued a “buy” rating and a $9.00 price objective for the company. Lake Street Capital upped their price objective on shares of Checkpoint Therapeutics from $4.00 to $7.00 and gave the company a “buy” rating in a report on Monday, December 16th. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Checkpoint Therapeutics in a report on Monday, December 16th.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of CKPT. Geode Capital Management LLC boosted its stake in Checkpoint Therapeutics by 41.2% during the third quarter. Geode Capital Management LLC now owns 427,651 shares of the company’s stock worth $958,000 after buying an additional 124,787 shares during the period. Wealth Enhancement Advisory Services LLC boosted its stake in Checkpoint Therapeutics by 160.0% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 130,000 shares of the company’s stock worth $291,000 after buying an additional 80,000 shares during the period. HB Wealth Management LLC lifted its position in shares of Checkpoint Therapeutics by 96.9% during the fourth quarter. HB Wealth Management LLC now owns 153,560 shares of the company’s stock worth $513,000 after purchasing an additional 75,560 shares in the last quarter. Walleye Capital LLC acquired a new stake in shares of Checkpoint Therapeutics during the third quarter worth about $148,000. Finally, Gladstone Institutional Advisory LLC lifted its position in shares of Checkpoint Therapeutics by 75.4% during the fourth quarter. Gladstone Institutional Advisory LLC now owns 61,399 shares of the company’s stock worth $196,000 after purchasing an additional 26,399 shares in the last quarter. Hedge funds and other institutional investors own 22.00% of the company’s stock.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.